The most commonly used treatment for Parkinson's disease (PD) is levodopa, prescribed in
conjunction with carbidopa. Virtually all patients with PD undergo dopamine replacement …

Levodopa‐induced dyskinesia is a common complication in Parkinson disease. Pathogenic
mechanisms include phasic stimulation of dopamine receptors, nonphysiological levodopa …

Involuntary movements, or dyskinesia, represent a debilitating complication of levodopa (L-
dopa) therapy for Parkinson's disease (PD). L-dopa-induced dyskinesia (LID) are ultimately …

Levodopa-induced dyskinesia (LID) is commonly seen in Parkinson's disease patients
treated with levodopa. This side effect is usually encountered after long duration of …

Dopamine replacement therapy with l-DOPA is the most efficacious symptomatic treatment
for Parkinson's disease, but its utility is limited by a development of motor fluctuations and …

Parkinson's disease (PD) is the second leading neurodegenerative disease that is
characterized by severe locomotor abnormalities. Levodopa (L-DOPA) treatment has been …

Dyskinesias encompass a variety of different hyperkinetic phenomenologies, particularly
chorea, dystonia, stereotypies, and akathisia. Levodopa-induced dyskinesia (LID) is one of …

Parkinson's disease (PD) significantly affects patients' quality of life and represents a high
economic burden for health systems. Given the lack of safe and effective treatments for PD …

Repurposing regulatory agency-approved molecules, with proven safety in humans, is an
attractive option for develo** new treatments for disease. We identified and assessed the …

Parkinson's disease (PD) is one of the most incapacitating neurodegenerative diseases
(NDDs). PD is the second most common NDD worldwide which affects approximately 1 to 2 …